<DOC>
	<DOCNO>NCT00034866</DOCNO>
	<brief_summary>The purpose research study determine three different dose combination tipranavir ritonavir , take standard approve anti-HIV drug therapy , effective safe . Tipranavir investigational protease inhibitor demonstrate vitro activity HIV-1 .</brief_summary>
	<brief_title>Dose Ranging Trial Tipranavir/Ritonavir Treatment-Experienced HIV Infected Individuals</brief_title>
	<detailed_description>This study conduct HIV+ , multiple ARV medication experience patient . All patient must receive treatment three ARV class : NRTIs , NNRTIs PIs , receive least two PI-based ARV regimen ( may include current regimen ) viral load great equal 1000 copies/mL time study entry . The two separate PI-based regimen must take least 3 month . At least one resistance-conferring PI-mutation ( pre-established panel ) must present . Baseline genotypic screening perform used conjunction ARV medication history determine new background therapy individual subject use . Following genotypic screen baseline , qualify subject randomize one three blind treatment regimen . Subjects discontinue current protease inhibitor initiate TPV/RTV 2 week functional monotherapy . Thereafter , background ARV medication optimize subject remain blinded TPV/RTV plus optimize background therapy duration trial . Trial duration range 12-32 week , depend subject enter trial interim analyse determination optimize TPV/RTV regimen complete . On determination optimal TPV/RTV dose , subject may opt continue open-label treatment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>1 . Signed informed consent prior trial participation . 2 . HIV1 infect male female &gt; = 18 year age . 3 . At least 3 month experience take NRTIs , NNRTI ( ) , PIs . 4 . Current PIbased ARV medication regimen least 3 month prior randomization , least 3 month experience take least one PIbased regimen . 5 . HIV1 viral load &gt; = 1000 copies/mL screen . 6 . Genotypic resistance report indicate one primary PI resistance mutation ( ) , include 30N , 46I/L , 48V , 50V , 82A/F/T , 84V 90M , one 82 A/F/T 84V 90M . 7 . Acceptable screen laboratory value indicate adequate baseline organ function . Laboratory value consider acceptable severity high Grade 3 GGT , Grade 2 cholesterol triglyceride , high Grade 1 test base DAIDS Grading Scale . All laboratory value outside limit subject approval BI . 8 . Acceptable medical history , assess investigator , chest Xray ECG within 1 year study participation . 9 . Willingness abstain ingest substance may alter plasma study drug level interaction cytochrome P450 system , : grapefruit Seville oranges product ; herbal preparation contain St. John ’ Wort milk thistle , garlic supplement . 10 . A prior AIDS defining event acceptable long resolve subject stable treatment least 2 month . 1 . ARV medication naïve . 2 . Female subject : positive serum pregnancy test screening study breast feed plan become pregnant willing use two barrier method contraception ( e.g . latex condom plus spermicidal jelly/foam ) . 3 . Any active opportunistic infection within 60 day study entry . 4 . Active Hepatitis B C disease define HBsAg positive HCV RNA positive AST/ALT &gt; Grade 1 . 5 . Prior tipranavir use . 6 . Use investigational medication within 30 day study entry trial . Some expand access drug may acceptable ; must approve BI . Tenofovir , investigational time preparation protocol , acceptable . 7 . Use concomitant drug may significantly reduce plasma level study medication . 8 . Use immunomodulatory drug ( e.g . interferon , cyclosporin , hydroxyurea , interleukin2 ) . 9 . Active substance abuse . 10 . Inability swallow TPV RTV capsule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>HIV</keyword>
	<keyword>treatment experience</keyword>
	<keyword>Boehringer</keyword>
	<keyword>tipranavir</keyword>
	<keyword>ritonavir</keyword>
</DOC>